Brief intro:
- Author: Ge Gao, Peiwen Xu, Chunyu Yang, Mengyuan Qian, Qingwen Wang, Surui Yao, Yuan Yin, Zehua Bian
- Journal: Transl Cancer Res
- Doi: https://www.doi.org/10.21037/tcr-2025-54
- Publication Date: 2025 May 23
Abstract
Background: Research has revealed that long non-coding RNAs (lncRNAs) are intimately associated with the occurrence, development, and metastasis of tumors through their regulation of gene expression. The lncRNA LINC00880 is important for colorectal cancer (CRC) occurrence and development. Our research aimed to explore the roles of LINC00880 in CRC progression.
Methods: The expression of LINC00880 in CRC cells and tissues was first measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and the prognosis of CRC patients was then investigated using the Kaplan-Meier method. The impacts of LINC00880 on CRC growth were evaluated by a series of in vitro and in vivo assays. Mechanistically, RNA sequencing (RNA-seq) technology and transcriptome analysis experiments were employed to validate the impact of LINC00880 on cell cycle pathway.
Results: In this study, we have demonstrated, for the first time, that LINC00880 is significantly overexpressed in CRC and is associated with poor patient survival. Functional assays indicated that LINC00880 promotes the growth of CRC cells both in vitro and in vivo. Furthermore, RNA-seq has revealed the impact of LINC00880 on the cell cycle and DNA replication pathways, and identified MCM3 as a potential downstream target of LINC00880.
Conclusions: Our findings indicate that LINC00880 is upregulated in CRC and promotes tumor growth.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
